EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development

Dennis Dong Hwan Kim, Gizelle Popradi, Kylie Lepic iD, Kristjan Paulson, David Allan iD, Ram Vasudevan Nampoothiri iD, Sylvie Lachance iD, Uday Deotare iD, Jennifer White, Mohamed Elemary iD, Kareem Jamani, Christina Fraga und 7 weitere

Current Oncology · 2024

DOI: 10.3390/curroncol31030108 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Current Oncology, 2024. Verfasst von Dennis Dong Hwan Kim und 18 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Bronchiolitis Obliterans Syndrome, Graft vs Host Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This is a consensus-based Canadian guideline whose primary purpose is to standardize and facilitate the management of chronic graft-versus-host disease (cGvHD) across the country. Creating uniform healthcare guidance in Canada is a challenge for a number of reasons including the differences in healthcare authority structure, funding and access to healthcare resources between provinces and territories, as well as the geographic size. These differences can lead to variable and unequal access to effective therapies for GvHD. This document will provide comprehensive and practical guidance that can be applied across Canada by healthcare professionals caring for patients with cGvHD. Hopefully, this guideline, based on input from GvHD treaters across the country, will aid in standardizing cGvHD care and facilitate access to much-needed novel therapies. This consensus paper aims to discuss the optimal approach to the initial assessment of cGvHD, review the severity scoring and global grading system, discuss systemic and topical treatments, as well as supportive therapies, and propose a therapeutic algorithm for frontline and subsequent lines of cGvHD treatment in adults and pediatric patients. Finally, we will make suggestions about the future direction of cGvHD treatment development such as (1) a mode-of-action-based cGvHD drug selection, according to the pathogenesis of cGvHD, (2) a combination strategy with the introduction of newer targeted drugs, (3) a steroid-free regimen, particularly for front line therapy for cGvHD treatment, and (4) a pre-emptive approach which can prevent the progression of cGvHD in high-risk patients destined to develop severe and highly morbid forms of cGvHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationBronchiolitis Obliterans SyndromeGraft vs Host DiseaseAdultHumansChildConsensusChronic DiseaseCanada

Stichwörter der Autor:innen

allogeneic hematopoietic stem cell transplantationchronic GVHDrecommendation

Autor:innen und Institutionen

  • Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
  • Health Centre, McGill University, Montreal, QC H4P 2P5, Canada.
  • Juravinski Cancer Centre, McMaster University, Hamilton, ON L8V 5C2, Canada.
  • CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, MB R3E 0V9, Canada.
  • Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
  • Hôpital Maisonneuve-Rosemont, Department of Medicine, University of Montreal, Montreal, QC H3C 3J7, Canada.

ORCID-Profile: Kylie Lepic, David Allan, Ram Vasudevan Nampoothiri, Sylvie Lachance, Uday Deotare, Mohamed Elemary, Christopher Lemieux, Igor Novitzky-Basso, Arjun Datt Law, Rajat Kumar, Irwin Walker

Zitieren

APA

Kim, D. D. H., Popradi, G., Lepic, K., Paulson, K., Allan, D., Nampoothiri, R. V., Lachance, S., Deotare, U., White, J., Elemary, M., Jamani, K., Fraga, C., Lemieux, C., Novitzky-Basso, I., Law, A. D., Kumar, R., Walker, I., Schultz, K. R., & CTTC Chronic GVHD Guideline Working Group (2024). Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development. Current Oncology. https://doi.org/10.3390/curroncol31030108

Vancouver

Kim DDH, Popradi G, Lepic K, Paulson K, Allan D, Nampoothiri RV, et al. Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development. Current Oncology. 2024. doi:10.3390/curroncol31030108

BibTeX
@article{Kim2024,
  author = {Kim, Dennis Dong Hwan and Popradi, Gizelle and Lepic, Kylie and Paulson, Kristjan and Allan, David and Nampoothiri, Ram Vasudevan and Lachance, Sylvie and Deotare, Uday and White, Jennifer and Elemary, Mohamed and Jamani, Kareem and Fraga, Christina and Lemieux, Christopher and Novitzky-Basso, Igor and Law, Arjun Datt and Kumar, Rajat and Walker, Irwin and Schultz, Kirk R and CTTC Chronic GVHD Guideline Working Group, CTTC Chronic GVHD Guideline Working Group},
  title = {Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31030108}
}
Kostenlos starten →